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The United Kingdom and United States have recently 
experienced large outbreaks of mumps, which raises con-
cerns about vaccine effectiveness. The effectiveness of the 
mumps component of the measles, mumps, rubella (MMR) 
vaccine was estimated using the screening method. In Eng-
land from January 2004 through March 2005, 312 cases of 
mumps were reported in children eligible to have received 2 
doses of MMR vaccine. Of these children, 52 (16.7%) had 
received 1 dose of MMR vaccine, and 97 (31.1%) had re-
ceived 2 doses. Vaccine effectiveness was 88% (95% con-
ﬁ  dence interval [CI] 83%–91%) for 1 dose and 95% (95% 
CI 93%–96%) for 2 doses. The effectiveness of 1 dose de-
clined from 96% (95% CI 81%–99%) in 2-year-olds to 66% 
(95% CI 30%–83%) in 11- to 12-year-olds, and the effective-
ness of 2 doses declined from 99% (95% CI 97%–99.5%) 
in 5- to 6-year-olds to 86% (95% CI 74%–93%) in 11- to 
12-year-olds (p<0.001 for 1 or 2 doses). Waning immunity 
may contribute to mumps outbreaks in older vaccinated 
populations.
I
n October 1988, immunization against mumps was in-
troduced in the United Kingdom as a single dose of mea-
sles, mumps, rubella (MMR) vaccine offered to all children 
12–15 months of age (1). Reports of disease declined 79% 
in the ﬁ  rst year, from 20,713 in 1989 to 4,277 in 1990. In 
1996, a second dose of MMR was introduced at school en-
try (2). From 1990 through 2003, the number of reported 
cases remained <5,000 per year (3), and since 1995, a high 
proportion of clinically diagnosed cases were shown by 
laboratory investigation not to be genuine mumps (4). 
During 2004–2005, a major increase in reported and 
conﬁ  rmed cases occurred in all regions of England and 
Wales. In 2005, >56,000 clinical cases were reported, most 
in patients 19–23 years of age (5). Of the conﬁ  rmed cases, 
<3% occurred in children eligible to have received 2 dos-
es of MMR vaccine routinely (i.e., those born from 1993 
through 1999) (5,6).
During 2005–2006, a large outbreak of mumps involv-
ing >2,500 possible cases from 11 states was reported in the 
United States (7). The reemergence of mumps in countries 
that had high levels of vaccine coverage for many years 
raises questions about the effectiveness of the mumps com-
ponent of the MMR vaccine and the possible contribution 
of waning immunity.
In early clinical trials, the efﬁ  cacy of a single dose of 
mumps vaccine was >95%, but estimates of the effective-
ness in ﬁ  eld evaluations have been 62%–85% (8–18). The 
possibility of waning immunity has been suggested in sev-
eral studies but not conclusively demonstrated (11–13,19). 
The UK outbreak offered the opportunity to evaluate the 
effectiveness of 1 or 2 doses of MMR vaccine and to inves-
tigate the presence of waning immunity by using routinely 
collected data.
Methods
We reviewed clinically reported mumps cases in Eng-
land from January 1, 2004, through March 31, 2005, that 
were conﬁ   rmed by oral ﬂ  uid  mumps-speciﬁ  c  immuno-
globulin M testing within 6 weeks of symptom onset (20). 
Only case-patients eligible to have received 2 doses of 
MMR vaccine through the routine program (i.e., those born 
after 1992) were included. Case-patients 3–5 years of age 
were excluded because children receive the second dose of 
MMR between these ages and, therefore, reliable popula-
tion coverage data are not available for comparison. Pos-
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sible vaccine-associated cases (i.e., symptom onset within 
6 weeks after vaccination) were also excluded. Vaccination 
histories were obtained from physician records or child 
health computerized recordkeeping systems.
Quarterly population vaccine coverage data for chil-
dren 2 and 5 years of age were obtained from the Cover of 
Vaccination Evaluated Rapidly program (21,22). Because 
of changes in health service boundaries and child health 
computerized recordkeeping systems, data for a small num-
ber of areas were missing for some quarterly periods. In ad-
dition, 5-year coverage data have been shown to underesti-
mate the true coverage in some areas (23). To compensate 
for this, coverage data were adjusted. Missing values were 
estimated using linear interpolation from the values sub-
mitted in previous and subsequent quarters. When cover-
age of ﬁ  rst-dose MMR for the same birth cohort was lower 
at 5 than at 2 years of age, the coverage at 5 years of age 
was assumed to be 3% higher than the value at 2 years of 
age (based on data from a sentinel surveillance scheme) 
(22). The adjusted data were used to approximate popula-
tion coverage for school-year cohorts (born from October 
1 through September 30 of the following year) to allow for 
similar levels of exposure within school years. Coverage 
data at 5 years of age for children born in 2000 were not 
yet available, so values were estimated from the previous 
cohort and data from the ﬁ  rst 2 quarters. Coverage data 
were divided into 2 categories, within and outside London, 
because coverage estimates are lower in London but fairly 
similar in the rest of the country (24).
Statistical Analysis
Vaccine effectiveness was calculated from the propor-
tion of conﬁ  rmed mumps cases vaccinated (PCV) and the 
proportion of the population vaccinated (PPV) using the 
following formula (25):
PPV ) PCV – 1 (
) ) PPV – 1 ( PCV ( – 1
ess effectiven Vaccine =
The data were grouped by school year, age, sex, and 
area of residence (within or outside London) and were ana-
lyzed by using logistic regression with an offset (incorpo-
rating expected PPV by area and birth cohort) for vaccine 
coverage. When estimating vaccine effectiveness for 1 
dose, those who had received 2 doses were excluded from 
the calculation of PPV. Similarly, those with only 1 dose 
were excluded when estimating vaccine effectiveness for 2 
doses. To estimate overall effectiveness, a model including 
only a constant was ﬁ  tted. Effectiveness in different sub-
groups was estimated from univariable models. If >1 vari-
able was statistically signiﬁ  cant on univariable analysis, 
multivariable analysis was performed.
Data from computerized child health systems, used 
for scheduling and recording vaccinations given, have 
consistently been shown to underestimate vaccine cover-
age (26,27). Sensitivity analyses explored the effects of 
possible underestimation of vaccine coverage by repeat-
ing calculations assuming that PPV was 1%, 2%, and 5% 
higher than that reported. Vaccine effectiveness estimates 
were also calculated using the unadjusted coverage data to 
examine the effect of data cleaning.
Estimating coverage in older children from a measure-
ment at 5 years of age could lead to an underestimate of 
effectiveness if there were a subsequent increase in cov-
erage. Therefore, we obtained data on children vaccinated 
with MMR after 5 years of age from the child health com-
puter system in the former South Thames region in 2000. 
Analyses explored the effect of an increase in coverage of 
0.04%–0.4% per year of age after 5 years of age. The pro-
portion of persons predicted to be susceptible to mumps, 
by age in England in 2005, was calculated by multiplying 
age-speciﬁ  c estimates of vaccine effectiveness by annual 
birth cohort coverage data.
Results
Vaccine Effectiveness
We found 312 conﬁ  rmed cases of mumps that were eli-
gible for inclusion. Vaccination history was obtained for all 
case-patients. The proportion of unvaccinated case-patients 
decreased with increasing age and was higher in younger 
birth cohorts (Table 1). The proportion of vaccinated case-
patients did not differ according to area of residence or sex.
Age at ﬁ  rst dose of MMR vaccine ranged from 10 
months to 5 years 9 months and at second dose from 16 
months to 6 years. Of those who had received MMR, >90% 
received the ﬁ  rst dose at 12–24 months of age and the sec-
ond dose at 3–5 years of age.
Adjusted population vaccine coverage declined during 
the study period (Table 2). Outside London, the percentage 
of children who received 1 dose of MMR by their second 
birthday declined from 92.7% to 82.7% from the 1993 to 
the 2002 birth cohort. The percentage who received 2 dos-
es by their ﬁ  fth birthday was more stable, declining from 
78.1% to 76.4% from 1993 to 2000. In London, estimates 
of coverage were lower and also declined over time.
Overall estimates of vaccine effectiveness were 87.8% 
(95% conﬁ  dence interval [CI] 83.1%–91.1%) for 1 dose 
and 94.6% (95% CI 92.9%–95.9%) for 2 doses. There 
was no statistically signiﬁ  cant variation in vaccine effec-
tiveness for 1 or 2 doses by area of residence (p = 0.3 for 
1 dose, p = 0.7 for 2 doses) or sex (p = 0.7 for 1 dose, 
p = 0.2 for 2 doses). Vaccine effectiveness decreased with 
increasing age for those who received either 1 or 2 doses 
(p<0.001) (Table 3). Vaccine effectiveness also varied with 
birth cohort (p = 0.02 for 1 dose, p = 0.003 for 2 doses). As 
birth cohort and age were correlated, it was not possible 
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to separate the effects of age group and birth cohort for 
1-dose effectiveness; the effect of birth cohort on 2-dose 
effectiveness was lost when adjusted for age. Application 
of our estimates of vaccine effectiveness to UK coverage 
data (Figure 1) predicts that >20% of children 11–12 years 
of age are not protected against mumps.
Sensitivity Analysis
Estimates of vaccine effectiveness using raw coverage 
data were 86.5% (95% CI 81.5%–90.3%) for 1 dose and 
96.8% (95% CI 95.6%–97.7%) for 2 doses. Estimates of 
vaccine effectiveness increased from 87.8% to 90.8% for 1 
dose and from 94.6% to 99.3% for 2 doses, for an increase 
in PPV of 1%–5% (Table 4).
Age at ﬁ   rst MMR vaccination was available for 
148,525 children registered on the South Thames child 
health computer system. In each birth cohort, 3–45 chil-
dren per year received the ﬁ  rst MMR dose at >5 years of 
age, most between 5 and 6 years of age. On average, an 
additional 0.04% (95% CI 0.036%–0.045%) of children re-
ceived MMR vaccine per year of age after their ﬁ  fth birth-
day. In the sensitivity analysis (Figure 2), a ﬁ  xed increase 
in coverage per year of age did not abolish the statistically 
signiﬁ  cant decline in vaccine effectiveness until coverage 
increased by at least 0.4% per year, 10× greater than that 
estimated from children in the South Thames region.Mumps Vaccine Effectiveness, England
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Discussion
Our estimate of 87.8% effectiveness for 1-dose mumps 
vaccine is lower than efﬁ  cacy estimates from clinical trials 
(8,9) but higher than those from most published ﬁ  eld evalu-
ations (10–14). Lower estimates in ﬁ  eld studies could result 
from problems with vaccine storage or administration, er-
rors in case deﬁ  nition (i.e., clinical instead of laboratory-
conﬁ  rmed cases) or ascertainment, inaccurate determina-
tion of vaccination status, and bias from conducting studies 
during outbreaks (10,28,29). Because clinical trials have 
relatively short follow-up periods, waning immunity may 
also produce lower observed effectiveness in ﬁ  eld evalu-
ations. We observed a decline in protection with increas-
ing age, which suggests that waning immunity may occur. 
After 2 doses, the magnitude of this decline is small, and 
effectiveness remains above >85% even 6–7 years after the 
second vaccination.
Research on whether protection from mumps vaccine 
declines with time since vaccination is contradictory. In 2 
US outbreaks, children vaccinated >5 (12) or >3 (19) years 
before each outbreak were at higher risk for mumps. In 2 
other US outbreaks, no evidence was found for increased 
infection rate with time since vaccination (11,16). A study 
from Belgium found increasing risk for disease with time 
since vaccination (13). In the presence of natural boosting, 
neutralizing antibodies have been demonstrated up to 12 
years after vaccination (30). However, duration of antibody 
persistence in a high-coverage setting where mumps cir-
culation has declined is not known. In Finland, a decline 
in mumps antibody titers was demonstrated in vaccinated 
children (31), and the proportion of children seropositive 
for mumps antibodies some years after MMR vaccination 
was lower than expected in Sweden and the United King-
dom (32,33).
Our estimates may be affected by several biases. Un-
vaccinated children may mix with other unvaccinated chil-
dren and exposure may be more common than in vacci-
nated children, which would lead to an overestimation of 
vaccine effectiveness. Because most cases occurred in age 
groups not eligible for vaccination, however, it is likely that 
exposure to mumps was fairly uniform. 
In addition, those who do not access healthcare for 
vaccination may be less likely to seek care for mumps dis-
ease. Consequently, these cases may be less likely to be re-
ported, which would lead to an underestimation of vaccine 
effectiveness. The availability of free universal primary 
care, however, means that persons with mumps should not 
have difﬁ  culty accessing medical care in the United King-
dom. Studies during local outbreaks may also underesti-
mate vaccine effectiveness, as a chance cluster of cases is 
more likely to be reported (29). The 2004–2005 outbreak 
of mumps was a national outbreak affecting all regions of 
the United Kingdom and is therefore unlikely to be subject 
to this bias (6).
The screening method relies on accurate estimates of 
population vaccine coverage (25). Estimates of vaccine ef-
fectiveness were similar using raw and adjusted coverage 
values, which suggests that our adjustments had not intro-
duced any major bias. Sensitivity analyses that explore the 
effects of underestimation of vaccine coverage demonstrate 
that overall effectiveness could be as high as 90% for 1 
dose, but this would require true coverage to be >5% higher 
than recorded.
If mumps cases had occurred before the period of our 
investigation, a false impression of waning immunity could 
have resulted because these cases would have affected pro-
portionately more unvaccinated than vaccinated children 
(34). Immunity develops in children who have had mumps, 
so unvaccinated children would be preferentially removed 
from the population at risk. Therefore, with increasing age, 
the proportion of mumps cases diagnosed in vaccinated 
children would increase. From 1990 through 2003, howev-
er, UK mumps incidence was extremely low, so past infec-
tion is unlikely to be responsible for the observed decline in 
vaccine effectiveness with increasing age.
The possible effect of migration to and from the Unit-
ed Kingdom on these estimates is difﬁ  cult to assess. Of im-
migrants to the United Kingdom, ≈80% arrive from com-
Figure 1. Estimates of the proportion of the population susceptible 
to mumps by age in 2005, applying study estimates of vaccine 
effectiveness to population coverage data.RESEARCH
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monwealth countries or the European Union each year, and 
≈40,000 are children <15 years of age (35). Some of these 
countries do not use routine mumps vaccine; therefore, our 
estimates of vaccine coverage in older children may be too 
high. This would lead to an apparent increase in effective-
ness with age, rather than the effect observed.
The use of vaccine coverage at the ﬁ  fth birthday as-
sumes that no further mumps vaccines are given after this 
age. If coverage gradually increased after this age, effec-
tiveness would be underestimated for older age groups. 
Children 5–12 years of age, however, have generally not 
been targeted by MMR catch-up campaigns, and the target 
payment incentive in primary care does not apply after 6 
years of age (36). From the South Thames data, most MMR 
given after the ﬁ  fth birthday is given to children 5–6 years 
of age, and the numbers vaccinated are too low to produce 
the observed decline in effectiveness. We therefore con-
clude that an increase in coverage after 5 years of age is 
unlikely to fully explain the decline.
No evidence has shown that vaccine quality and han-
dling changed over time. All cohorts >6 years of age were 
only eligible for MMR-II (Sanoﬁ   Pasteur MSD, Berkshire, 
UK) for the ﬁ  rst dose, so a change in product cannot be 
responsible for the decline in ﬁ  rst-dose effectiveness after 
this age. Priorix (GlaxoSmithKline, Uxbridge, UK) became 
available in 1998, but as population coverage by vaccine 
manufacturer is not available, we are unable to show any 
differences between vaccines.
According to this study, <80% of children 11–12 years 
of age are protected against mumps, less than the suggested 
threshold of 90%–92% to interrupt transmission (37). The 
true proportion of those with immunity may now be higher 
than this because many unvaccinated persons will have ac-
quired natural infection and vaccinated persons may have 
been boosted by exposure during the outbreak.
Our estimates of vaccine effectiveness suggest that the 
mumps component of MMR provides excellent protection 
through routine administration in the United Kingdom. The 
observation of waning immunity is, however, a cause for 
concern because the proportion of susceptible adolescents 
may increase, which could lead to future outbreaks in this 
age group. Because most recent cases have occurred in per-
sons too old to have been vaccinated, the contribution of 
waning immunity to the current UK outbreak is small (6). To 
minimize the risk of future outbreaks, MMR vaccine cover-
age with both doses must be improved and maintained.
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